Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Study in 338 consecutive patients with type 2 diabetes and COVID-19 admitted to hospitals in Northern Italy found that addition of stigliptin to standard of care at the time of hospitalisation was associated with reduced mortality (18% vs. 37% HR 0.44, 95%CI 0.29–0.66).

Diabetes Care